Clinical Scorecard: Impact of Repetitive Transcranial Magnetic Stimulation on Outcomes in Patients with Postherpetic Neuralgia and Concurrent Depression Receiving Interventional Neuromodulation

At a Glance

Key Highlights

• PHN often coexists with depression, creating a vicious cycle that worsens symptoms and treatment outcomes.
• Interventional neuromodulation therapies like pulsed radiofrequency and spinal cord stimulation are effective but have up to 32.6% poor prognosis rates.
• 10 Hz high-frequency rTMS shows potential to improve pain, sleep quality, mood, and overall prognosis when combined with interventional neuromodulation.

Guideline-Based Recommendations

Diagnosis

• Diagnose PHN as pain persisting >1 month after rash resolution.
• Assess depression severity using validated scales such as the Self-Rating Depression Scale (SDS).
• Evaluate pain intensity using Visual Analog Scale (VAS) or Numeric Rating Scale (NRS).

Management

• Employ interventional neuromodulation therapies (e.g., pulsed radiofrequency, spinal cord stimulation) for refractory PHN.
• Consider adjunctive 10 Hz rTMS targeting the primary motor cortex to alleviate pain and depressive symptoms.
• Use pharmacological agents such as pregabalin, tramadol, or antidepressants as needed.

Monitoring & Follow-up

• Monitor pain intensity, sleep quality, depression scores, patient satisfaction, and functional disability using validated scales (VAS, SF-MPQ, SDS, PDI, MFI-20).
• Track medication dosages and requirements for analgesics and antidepressants.
• Assess safety outcomes including headache, local pain, neck pain, insomnia, muscle soreness, dizziness, nausea, tinnitus, irritability, tachycardia, and seizure activity.

Risks

• Potential adverse effects of rTMS include headache, local pain at stimulation site, neck pain, insomnia, muscle soreness, dizziness, nausea, tinnitus, irritability, tachycardia, and rare risk of epilepsy.
• Persistent moderate to severe pain and emotional distress may require repeated interventions or pharmacological adjustments.

Patient & Prescribing Data

Adults with PHN and mild to moderate depression undergoing interventional neuromodulation

rTMS adjunctive therapy may reduce the need for higher doses of pregabalin, tramadol, or antidepressants by improving pain and mood outcomes.

Clinical Best Practices

• Integrate assessment and management of depression in patients with PHN to address the bidirectional impact on pain and mood.
• Apply high-frequency (10 Hz) rTMS targeting the primary motor cortex as an adjunct to interventional neuromodulation therapies.
• Use a randomized, double-blind, placebo-controlled trial design to evaluate efficacy and safety of rTMS in this population.
• Employ validated scales for comprehensive evaluation of pain, mood, sleep, fatigue, and functional disability.
• Monitor for and manage potential adverse effects related to rTMS and interventional therapies.

References

• Trial registration ChiCTR2500096978